AbsTrAcT: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a prognosis that can be worse than for many cancers. The initial stages of the condition were thought to mainly involve chronic inflammation; therefore, corticosteroids and other drugs that have antiinflammatory and immunosuppressive actions were used. However, recently, agents targeting persistent fibrosis resulting from aberrant repair of alveolar epithelial injury have been in the spotlight. There has also been an increase in the number of available antifibrotic treatment options, starting with pirfenidone and ninte danib. These drugs prevent deterioration but do not improve IPF. Therefore, nonpharmacologic approaches such as longterm oxygen therapy, pulmonary rehabilitation, and lung transplantation must be considered as additional treatment modalities.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in adults and is limited to the lungs. It has been associated with a histopathologic and/ or radiologic pattern of usual interstitial pneumonia. 1 The prog nosis is very poor, with a mean survival of about 2.5-5 years after definite diagnosis -a harsh prognosis that makes it inap propriate to refer to IPF as a benign disease. 2 The natural history of IPF is highly variable and the course of the dis ease for each individual patient is difficult to predict. Some patients experience rapid decline, others progress much more slowly, and some have periods of relative stability interspersed with acute deteriorations (Fig. 1) . Once an acute exacerbation occurs, recovery is extremely difficult. Furthermore, because the condition essentially involves structural changes and develops in elderly people, treatment of complications is very challenging for a variety of reasons, including cardiovascular events, pulmonary hypertension, lung cancer, and so on. In recent years, the introduction of pirfenidone and nintedanib treatment has led to many attempts to develop similar drugs for IPF. Although many drugs for IPF have been validated in clinical trials, no therapeutic methods have led to cure. In this article, we aimed to discuss the present treatment approaches and prognosis of IPF, with focus on the available drug options and nonpharmacologic approaches.
Guidelines on IPF Diagnosis and Treatment before 2015
Policies for diagnosis and management of IPF were acce pted based on the international consensus statement by the American Thoracic Society (ATS)/European Respiratory Soci ety (ERS)/Japanese Respiratory Society (JRS)/Asociación Latino americana de Tórax (ALAT) in 2011. 1 In this guideline, the period of literature search was from 1996 to 2010, when there was almost no evidence on IPF treatment. Because there were no therapeutic methods providing significant shortterm effects and because the disease is fundamentally a chronic progressive condi tion, the main objective has been prevention of disease progression over time. Therefore, IPF therapies must include ways to not only improve symptoms but also ensure adequate clinical stability.
Initially, corticosteroids and immunosuppressants were used to treat IPF because chronic inflammation was believed to be the cause of persistent fibrosis in the early stages of the condi tion. However, opinion has gradually changed to that of abnormal repair of alveolar epithelial injury leading to persistent fibrosis, 3 which should be the principal concern of disease management. 4 Therefore, pirfenidone and other antifibrotic agents have taken 
Pharmacologic Therapies
In the ATS/ERS/JRS/ALAT statement in 2011, there were no pharmacologic therapies shown to have clear and satis factory results. Nevertheless, the 2015 updated guideline described conditional recommendations, based on some clin ical studies, about the benefits and disadvantages of certain drugs for IPF (Table 2) . However, even if a certain drug was recommended by some, the question of individuals who should be considered for pharmacotherapy remains uncer tain. The patients included in the trials had mild to mod erate disease. On the other hand, severe patients should be maintained on pharmacotherapy and should be considered to receive nonpharmacologic therapies. Reduction of mortality is a desirable end point to assess the efficacy of these drugs, but this would be costly and entail analyzing a large number of cases. For this reason, respira tory function and exercise tolerance tests have been adopted as surrogate end points. Forced vital capacity (FVC) has often been used as the main end point in recent clinical studies. 
Notes:
The natural history of idiopathic pulmonary fibrosis (IPF) is highly variable, and the course of the disease in an individual patient is difficult to predict. some patients experience rapid decline, others progress more slowly, and some patients remain stable. some patients may experience acute exacerbation of the disease, which might be fatal. Low baseline values, as well as 6 and 12month decreases in FVC, were reported to correlate with mortality rates. 6 FVC change of 10% or more was a definite prognostic factor in IPF. 7 Moreover, although IPF prognosis is determined by var ious factors, FVC is reproducible and might be considered the most suitable surrogate end point for vital prognosis. 8 In our opinion, standardizing differences, including race, is one of the challenges when planning international clinical studies.
Pirfenidone. Pirfenidone is a lowmolecularweight com pound with antiinflammatory effects, and it has been found to have antifibrotic action as well. The antifibrotic property of pir fenidone is believed to depend on its ability to inhibit fibroblast proliferation, collagen biosynthesis, and production of trans forming growth factor beta and tumor necrosis factor alpha and on its ability to induce antiinflammatory and antioxidant effects. [9] [10] [11] [12] A placebocontrolled phase II randomized con trolled trial (RCT) was conducted. 13 The total number of cases was 107, and they were categorized into a group (n = 72) receiv ing pirfenidone (1800 mg/day) and a placebo group (n = 35). There was no difference between the two groups in terms of the main end point, which was change in lowest oxygen saturation from baseline after a 6minute exercise test (6minute walk test or 6MWT); however, vital capacity (VC) significantly improved in the pirfenidone group. 13 Considering these results, a placebocontrolled phase III RCT was conducted.
14 Three groups according to pirfenidone doses were assigned: high dose (1800 mg/day) (n = 108), low dose (1200 mg/day) (n = 55), and placebo (n = 104). At 52 weeks, significant differences were observed in the VC decline from baseline between the placebo (-160 mL) and highdose (-90 mL) groups, as well as between the lowdose (-80 mL) and the placebo (-160 mL) groups. Based on these results, pirfenidone was approved in October 2008 for IPF therapy in Japan; this was the first approval for IPF drug marketing in the world.
On the other hand, the CAPACITY (studies 004 and 006) clinical trials 15 on pirfenidone for IPF were conducted in parallel at multinational institutions. Both studies were placebocontrolled, phase II RCTs. In the CAPACITY study 004, pirfenidone was shown to be effective based on a signifi cant difference in the main end point, which was change in %FVC from baseline to 72 weeks (pirfenidone group, -8.0% versus placebo group, -12.4%). In contrast, study 006 did not show a similar significant change in baseline %FVC at 72 weeks (pirfenidone group, -9.0% versus placebo group, -9.6%). Based on these results, the US Food & Drug Administration (FDA) withheld the approval of pirfenidone in May 2010, and further clinical study was required. On the other hand, in Europe, the drug began to be marketed in Ger many in September 2011; afterward, the number of countries that approved pirfenidone use gradually increased. A phase III study (ASCEND) 16 was conducted in North America and Oceania to verify the effects of pirfenidone on 555 patients with IPF. After 52 weeks, baseline indexes of IPF progression, including FVC, 6minute walk distance, and progressionfree survival, improved in the pirfenidone group compared with the placebo group (change in FVC: pirfeni done group, -235 mL versus placebo group, -428 mL). In this study, the authors analyzed mortality in the pooled population from the ASCEND 16 and CAPACITY 15 trials and showed that pirfenidone reduced the risk of death at 1 year by 48%, compared with placebo. Considering the acceptable results of the ASCEND study, 16 pirfenidone was approved for market ing by the FDA in October 2014.
The commonly reported adverse events of pirfenidone were gastrointestinal (nausea, dyspepsia, vomiting, and anorexia), skinrelated (rash and photosensitivity), and neu rologic (headache and dizziness) symptoms; fatigue; and elevated hepatic enzyme levels. These events were gener ally mild or moderate in severity, in addition to being dose dependent to some extent. Based on our experience, we ini tially prescribe pirfenidone at 600 mg/day before gradually (at least every 2 weeks) increasing to the standard dose of 1800 mg/day. In case of significant adverse events, we reduce the dose to 1200 mg/day.
Nintedanib. Nintedanib blocks the signal transduction pathway of vascular endothelial growth factor receptors, plateletderived growth factor receptors, and fibroblast growth factor receptors (triple kinase inhibitor) 17, 18 to inhibit progres sion of IPF and worsening of respiratory function. In fact, in a phase II study (TOMORROW), 19 nintedanib was found to inhibit the decline in pulmonary function and acute exac erbation in patients with IPF (change in baseline FVC at 52 weeks: nintedanib group, -60 mL versus placebo group, -190 mL). Furthermore, two randomized, doubleblind, phase III reproducibility studies (INPULSIS1 and 2) were conducted for more than 52 weeks to evaluate the efficacy and safety of twicedaily administration of nintedanib (150 mg) in patients with IPF. 20 The main end point was annual rate of decline in FVC, and the secondary end points were time to first acute exacerbation and changes in the St George's Respi ratory Questionnaire (SGRQ ) score. A total of 1066 cases were randomly assigned with a nintedanib:placebo ratio of 3:2. The annual rate of FVC decline from baseline was signifi cantly suppressed after 52 weeks in both INPULSIS1 (nin tedanib group, -114.7 mL versus placebo group, -239.9 mL) and INPULSIS2 (nintedanib group, -113.6 mL versus pla cebo group, -207.3 mL). Differences between the nintedanib and placebo groups in terms of time to first acute exacerbation and SGRQ score were not significant in INPULSIS1 but were significant in INPULSIS−2. Because the results of these studies were considered acceptable, the FDA approved nin tedanib for IPF treatment on the same date that pirfenidone was approved (October 2014). To date, many of potentially effective options are in the development stage for the treat ment of IPF.
The most frequent adverse event of nintedanib is diar rhea. In the CAPACITY trial, 15 more than 90% of patients experienced diarrhea, but only less than 5% were compelled to discontinue nintedanib. Another common adverse event is elevated hepatic enzyme levels. The standard dose of ninte danib is 150 mg twice a day, but in case of significant adverse events, the dose may be reduced to 100 mg twice a day. corticosteroids and immunomodulators. A combina tion therapy of prednisone, azathioprine, and NAC is widely used for IPF; however, the safety and effects of this regi men have not been well understood until recently. Therefore, a randomized, doubleblind, placebocontrolled PANTHER IPF study was conducted by the US National Institutes of Health on 35 to 85yearold patients with mildtomoderate IPF who were assigned to the following groups: prednisone + azathioprine + NAC; NAC only; and placebo. 21 The primary outcome was change in baseline FVC after 60 weeks. In the interim analysis, the number of deaths was eight in the com bination group and one in the placebo group. The risk of death was significantly high, and there was a need for frequent and unscheduled hospital admissions (23 cases versus seven cases, respectively). Based on the results of interim analysis, the Data and Safety Monitoring Board recommended discontinuation of the threedrug combination use. In addition, the updated treatment guidelines for IPF strongly recommended against use of corticosteroids and immunosuppressants with NAC for IPF. 5 N-Acetylcysteine. Oxidative stress causes alveolar epi thelial cell injury, which leads to lung fibrosis. In normal indi viduals, redox balance is maintained by superoxide dismutase and glutathione; this balance is disturbed in patients with IPF. NAC not only has antioxidant properties as a glutathione precursor, but it can also act as a direct reactive oxygen scaven ger, which is thought to mediate its antifibrotic effect. In the IFIGENIA study conducted in Europe, comparison was made between an NAC group (prednisone + azathioprine + NAC) and a control group (prednisone + azathioprine). 22 In this study, reduction of the main end points, VC and diffusing capacity of the lungs for carbon monoxide (DLCO), was significantly inhibited in the NAC group. On the other hand, there was minimal myelosuppression in the NAC group because gluta thione cell concentration was increased by NAC. In addition, liver cell injury was observed, and the side effects commonly associated with azathioprine administration were reduced. On the other hand, comparative evaluation between placebo and NAC alone in the PANTHERIPF study disclosed no sig nificant differences in the following: rate of FVC change from baseline to 60 weeks of treatment, survival, and frequency of acute exacerbation. 22 Therefore, administration of NAC alone has no significant benefit in IPF. However, in Japan, therapy with combined pirfenidone and inhaled NAC remains a pos sibility in the clinical setting.
Antacid therapy. Gastroesophageal reflux disease, including asymptomatic cases, has been observed in more than 90% of patients with IPF. 23 Abnormal reflux is a risk factor for aspiration, which could cause pneumonia and contribute to chronic airway inflammation and fibrosis. In addition, aspi ration pneumonia can worsen IPF and could be a risk factor for acute exacerbation. Therapy with antacids, such as proton pump inhibitors (PPIs) and histamine2 receptor antagonists (H2RAs), may decrease this risk for aspiration pneumonia associated lung injury or damage. A retrospective analysis of longitudinal cohorts suggested benefit for IPF patients who received PPIs and H2RAs (hazard ratio [HR]: 0.47; 95% con fidence interval [CI]: 0.24-0.93; adjusted analysis). 24 Another aggregate analysis of data from three RCTs showed a signifi cantly smaller decrease in FVC in IPF patients who received antiacid treatment at baseline. 25 comparison between pirfenidone and nintedanib. As described earlier, the FDA approved both pirfenidone and nintedanib for the treatment of IPF. Evidence for changes in FVC showed a significantly slower decline in patients treated with pirfenidone or nintedanib compared with placebo. At present, there is no clear evidence regarding which drug is superior. A recent systematic review that indirectly compared both drugs based on network metaanalysis reported slower decline in FVC in patients treated with nintedanib com pared with those who received pirfenidone. 26 Nintedanib was significantly better than placebo in decreasing acute exacer bations, whereas pirfenidone was significantly better than placebo in decreasing mortality. By indirect comparison, all cause mortality was lower with pirfenidone than with ninte danib, but this was not significant (odds ratio [OR]: 1.39; 95% CI: 0.70-2.82). Based on these results on clinical efficacy, the superior firstline therapy for IPF remains to be determined. On the other hand, profiles of side effects are slightly differ ent between the two drugs. Gastrointestinal and skinrelated events were more common in the pirfenidone group, 16 whereas diarrhea and liver dysfunction were more common in the nin tedanib group. 20 Taking into account these various factors, the choice between pirfenidone and nintedanib for IPF must be individualized.
Nonpharmacologic Therapies
Long-term oxygen therapy. Pronounced hypoxia during physical exertion is a characteristic finding in IPF patients. In fact, hypoxia during the 6MWT is related to prognosis. 27 There are no data on the use of longterm oxygen therapy in patients with IPF, but it was strongly recommended in the international guidelines by the ATS/ERS/JRS/ALAT.
1
Lung transplantation. The first successful lung trans plantation was conducted in 1983 on a 58yearold man with IPF. 28 Because IPF has a poor prognosis and no supereffective drugs exist, lung transplantation is commonly considered for patients with moderate to severe disease. 1 However, it is very difficult to determine when a patient can be registered in the transplant list. In 2006, the International Society for Heart and Lung Transplantation released guidelines on the selection of lung transplant candidates, as follows: predicted DLCO of less than 39%; 10% or greater decrease in FVC during 6 months of followup; a decrease in oxygen saturation below 88% during 6MWT; and honeycombing on highresolution computed tomography scan (fibrosis score of .2).
29 Age more than 65 years is a relative contraindication. In patients with underlying IPF, superiority between bilateral and single lung transplantation is unclear. 5 The 5year survival rate after lung transplantation in IPF was estimated at about 50%.
30
Pulmonary rehabilitation. Pulmonary rehabilitation including aerobic conditioning, strength and flexibility train ing, educational lectures, nutrition advice, and psychoso cial support may be beneficial for IPF patients, especially to improve activities of daily living (ADL) and quality of life (QOL). 31 The effects of pulmonary rehabilitation may be more effective in patients with worse baseline functional sta tus. 32 Pulmonary rehabilitation is weakly recommended in the international guidelines of the ATS/ERS/JRS/ALAT because the longterm benefit of pulmonary rehabilitation remains unclear and may not be reasonable in a minority.
expected Novel Therapeutics
Many molecules are currently in different stages of development for use in the treatment of IPF. Table 3 presents an overview of the most advanced molecules and pathways being targeted. abbreviations: il, interleukin; mtor, mammalian target of rapamycin; tgF, transforming growth factor.
33
The diversity of the pathways being targeted these days, when compared with previous studies, reflects our improved understanding of disease pathobiology. Especially, therapies with monoclonal antibodies in addition to various inhibitors are increasing. Based on the different mechanisms of action between nintedanib and pirfenidone, it would be worthy to evaluate the combined efficacy of both molecules. 34 A recent randomized, doubleblind, phase II, doseescalation trial on nintedanib plus pirfenidone 35 showed that pirfenidone tended to decrease the maximum plasma concentration of nintedanib; on the other hand, nintedanib had no effect on the pharmacokinetics of pirfenidone. Further studies are needed to evaluate the efficacy and safety of this combined therapy. Results of a clinical trial (NCT01872689) on a combination therapy with pirfenidone and lebrikizumab (antiIL13) are likewise anticipated. Table 4 shows the prognostic factors in IPF patients. 1 The definite indexes of IPF prognosis are factors that change over time; these include symptoms, respiratory function, and imaging. 1 These are important points to consider when exam ining the clinical progression of IPF.
Prognosis
The cause of IPF is still unknown and it is thought to be a heterogeneous condition. Even with a slow start, the dis ease can sometimes progress rapidly. 36 In addition to having variable progression, IPF remains an incurable disease with poor prognosis. Studies are currently under way to identify the heterogeneous conditions of the disease. Additional and new end points are being anticipated in the future. Currently, the end point used to judge treatment efficacy is clinical improve ment and stability of disease. Several studies are being under taken to develop novel markers of poor prognosis. However, as shown in Table 2 , many largescale studies on several drugs have shown negative results. Unfortunately, as long as there is no breakthrough in drug development, there will be no chance to improve prognosis in IPF.
In general, the reported results on prognosis were based on studies in which the median duration of followup was 2.5-5 years. 2 Further, the prognosis of IPF was even poorer than that of many types of cancer. 37 This mortality outcome in IPF has been due to acute exacerbation in many of the cases. In Japan, acute exacerbation has become the most frequent cause of death in up to 40% of cases. 38 However, in some instances, the disease may unpredictably slow down after a rapid pro gression (Fig. 1) . At present, prediction of individual clinical course is not possible; therefore, efforts must be made to find simple and accurate prognostic markers. One easy, simple, and useful marker that has been proposed for predicting IPF prog nosis is the GAP score risk prediction model, which includes four factors: gender (G), age (A), and two lung physiologic (P) variables (FVC and DLCO). 39 Since G and A are non modifiable variables, improvement of pulmonary function by novel pharmacologic and nonpharmacologic therapies must be developed to improve the prognosis of IPF.
conclusions
IPF is an intractable respiratory disease with poor prognosis. Several novel therapeutic drugs have been developed, but only a few have demonstrated efficacy in RCTs. These promising drugs include pirfenidone and nintedanib, which are presently available in many countries. Several other drugs are presently undergoing either clinical studies or basic research in the non clinical stages. In the near future, we expect breakthrough ther apies that can lead to improvement of survival in IPF patients.
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